<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712593</url>
  </required_header>
  <id_info>
    <org_study_id>15NRHC</org_study_id>
    <nct_id>NCT02712593</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Effects of Niagen™ in Healthy Adults.</brief_title>
  <acronym>15NRHC</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled Parallel Study Investigating the Effects of Niagen™ (Nicotinamide Riboside) on Niagen™ Metabolites in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ChromaDex, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of repeated doses of Niagen™ on Niagen™ metabolite&#xD;
      concentrations in blood, urine and muscle. There will be 3 doses of Niagen™ compared to a&#xD;
      placebo. One quarter of subjects will receive the low dose of Niagen™, one quarter will&#xD;
      receive the moderate dose of Niagen™, one quarter will receive the higher dose of Niagen™ and&#xD;
      one quarter will reveive the placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 17, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Methylnicotinamide</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Change in levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Nicotinamide Riboside Metabolites</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Change in levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Nicotinamide Riboside Metabolites</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Change in levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Nicotinamide Riboside Metabolites</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Change in Levels of Metabolites Assessed from Muscle Tissue collected with Micro-Needle Biopsy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Change in Levels (kcal/day) Assessed by the ReeVue Indirect Calorimeter</description>
  </other_outcome>
  <other_outcome>
    <measure>Expression profile: Branched Amino Acids</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Expression profile: high sensitivity C-reactive protein</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Abnormal Vital Signs</measure>
    <time_frame>8 weeks: from baseline to end of study</time_frame>
    <description>Resting blood pressure</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Abnormal Laboratory Values</measure>
    <time_frame>8 weeks: baseline to end of study</time_frame>
    <description>Assessment of hematology and clinical chemistry parameters: CBC, electrolytes (Na, K, CL), AST, ALT, GGT, BUN, HDL, LDL, triglycerides and total cholesterol</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>8 weeks: baseline to end of study</time_frame>
    <description>Review of adverse events</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>Niagen™ 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Niagen™ 300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Niagen™ 1000</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen™ 100</intervention_name>
    <arm_group_label>Niagen™ 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen™ 300</intervention_name>
    <arm_group_label>Niagen™ 300</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen™ 1000</intervention_name>
    <arm_group_label>Niagen™ 1000</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 25-30kg/m²&#xD;
&#xD;
          -  If female, subject is not of child bearing potential, which is defined as females who&#xD;
             have had a hysterectomy or oophorectomy, bilateral tubal ligation or are&#xD;
             post-menopausal (natural or surgically with &gt; 1 year since last menstruation) OR&#xD;
             Females of childbearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods of&#xD;
             birth control include:&#xD;
&#xD;
               -  Hormonal contraceptives including oral contraceptives, hormone birth control&#xD;
                  patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable&#xD;
                  contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)&#xD;
&#xD;
               -  Double-barrier method&#xD;
&#xD;
               -  Non-hormonal intrauterine devices&#xD;
&#xD;
               -  Vasectomy of partner&#xD;
&#xD;
          -  Healthy as determined by laboratory results, medical history, and physical exam&#xD;
&#xD;
          -  Agrees to comply with study procedure&#xD;
&#xD;
          -  Agrees to maintain current level of physical activity throughout the study and avoid&#xD;
             exercising on the day of study visits 3 to 7 (prior to the visit).&#xD;
&#xD;
          -  Agrees to refrain from consuming caffeine (i.e. coffee) on the days of study visits 3&#xD;
             to 7 (prior to the visit)&#xD;
&#xD;
          -  Agrees to avoid taking Vitamin B3 (niacin, nicotinic acid,niacinamide) supplements or&#xD;
             multivitamins 14 days prior to randomization and for the duration of the study period&#xD;
&#xD;
          -  Has given voluntary, written, informed consent to participate in the study&#xD;
&#xD;
          -  Agrees to avoid foods that contain high amounts of tryptophan and niacin and limit&#xD;
             their ingestion of foods containing moderate amounts of tryptophan and niacin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Alcohol use &gt;2 standard alcoholic drinks per day&#xD;
&#xD;
          -  History of alcohol or drug abuse within the past year&#xD;
&#xD;
          -  Medicinal use of marijuana&#xD;
&#xD;
          -  Diabetes (Type I or Type II)&#xD;
&#xD;
          -  Subjects taking lipid lowering drugs&#xD;
&#xD;
          -  History of renal and/or liver disease&#xD;
&#xD;
          -  History of pellagra or niacin deficiency&#xD;
&#xD;
          -  Significant or untreated medical disorders including recent myocardial ischemia or&#xD;
             infarction, unstable angina, uncontrolled hypertension, AIDS, malignancy, and&#xD;
             neurological disorders including epilepsy, and recent cerebrovascular disease&#xD;
&#xD;
          -  Subjects with or who had recently experienced a traumatic injury, inflammation,&#xD;
             infections or had undergone surgery&#xD;
&#xD;
          -  Use of natural health products containing NR within 14 days prior to randomization and&#xD;
             during the course of the study&#xD;
&#xD;
          -  Unstable medical conditions as determined by the Qualified Investigator&#xD;
&#xD;
          -  Clinically significant abnormal lab results at screening (e.g. AST and/or ALT &gt; 2 x&#xD;
             ULN, and/or bilirubin &gt; 2 x ULN) will be assessed by the Medical Investigator&#xD;
&#xD;
          -  History of or current diagnosis of any cancer (except for successfully treated basal&#xD;
             cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer&#xD;
             in full remission more than 5 years after diagnosis are acceptable&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to randomization&#xD;
&#xD;
          -  Allergy or sensitivity to study supplement ingredients&#xD;
&#xD;
          -  Allergy or sensitivity to lidocaine&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Serum creatinine ≥ 130µmol/L for males and ≥ 125µmol/L for female&#xD;
&#xD;
          -  Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or which may pose significant risk to the&#xD;
             subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gordon Schacter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Science Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy participants</keyword>
  <keyword>Dietary supplement</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Niagen™</keyword>
  <keyword>Nicotinamide riboside</keyword>
  <keyword>N-methylnicotinamide</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

